What is Tesamorelin?
A lab-made analog of the body's full 44-amino-acid growth-hormone-releasing factor (GHRF/GHRH), with a hexenoyl group added at one end, prepared as an acetate salt.
US legal status
Open question
Whether any pharmacy may compound tesamorelin today is not settled. The FDA's own documents say the law "does not provide a legal pathway" for biological products made outside an approved license, yet programs sell compounded tesamorelin.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
On the FDA label
- The EGRIFTA SV and WR labels say not to use it with a disrupted hypothalamic-pituitary axis (after pituitary surgery or a pituitary tumor, head radiation or head injury), with active cancer, with allergy to tesamorelin or its inactive ingredients, or in pregnancy.12
- The labels warn of a higher risk of tumors (neoplasms), because it releases growth hormone, "a known growth factor". They say any earlier cancer must be inactive and treated first, and to stop if cancer comes back.1
- The labels say "The effects of prolonged elevations in IGF-1 levels are unknown." At 26 weeks, 47% of patients had IGF-1 above 2 standard deviation scores (SDS) and 36% above 3 SDS, and the labels say to monitor IGF-1.1
- The labels warn of fluid retention: swelling (edema), joint pain and carpal tunnel syndrome, which pass or resolve after stopping.1
- The labels report an HbA1c of 6.5% or more in 5% of patients versus 1% on placebo (hazard ratio 3.3). They say to check glucose before and during treatment, and to watch for eye damage (retinopathy) in people with diabetes.1
- The labels report allergic reactions in 4% of patients (itching, redness, flushing, hives, rash) and injection-site reactions in 25% versus 14% on placebo. They say to consider stopping in acute critical illness.1
- In the labels' 26-week table (543 people on EGRIFTA, 263 on placebo), the reactions were: injection-site reaction 17% vs 6%, joint pain 13% vs 11%, pain in a limb 6% vs 5%, muscle pain 6% vs 2%, swelling of the limbs (peripheral edema) 6% vs 2%, tingling 5% vs 2%, numbness 4% vs 2% and rash 4% vs 2%. In all, 740 people were treated in trials.1
- The labels report "no clinically significant changes" in TSH, LH, ACTH or prolactin in trials.1
- The labels report hydrocephaly in the offspring of rats given about 2 to 4 times the amount used in patients, and advise against breastfeeding (HIV transmission and unknown effects). They say it is not indicated for children and may speed their growth, and have "no information" on people over 65.1
Reports to the FDA
- The FDA's adverse event database (FAERS, data to October 28, 2026) holds 3,625 reports naming tesamorelin or EGRIFTA, 840 marked serious; the most frequent terms are "product dose omission" (311), joint pain (286), injection-site pain (274), "drug ineffective" (193), weight increased (191), "incorrect dose" (178), injection-site bruising (163) and pain in a limb (163). Only 13 reports name "tesamorelin" as the product and nearly all name EGRIFTA, so FAERS says almost nothing about compounded tesamorelin; the reports are not checked, and they do not show cause.27
No data
Product quality
Compounded tesamorelin is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
- 1.EGRIFTA SV (tesamorelin) prescribing information, set id 3d783378 (effective 2026-07-29), via openFDA / DailyMedTier 1: regulator or registerdailymed.nlm.nih.govread Nov 16, 2026↩
- 2.EGRIFTA WR (tesamorelin) prescribing information, set id 839334d3 (effective 2026-07-29)Tier 1: regulator or registerdailymed.nlm.nih.govread Nov 16, 2026↩
- 3.Drugs@FDA: BLA 022505 (EGRIFTA)Tier 1: regulator or registeraccessdata.fda.govread Nov 16, 2026↩
- 4.Approval letter, BLA 022505/S-020: EGRIFTA WR (Mar 25, 2025)Tier 1: regulator or registeraccessdata.fda.govread Nov 16, 2026↩
- 5.EGRIFTA 2 mg/vial label (S-010, revised Nov 2018)Tier 1: regulator or registeraccessdata.fda.govread Nov 16, 2026↩
- 6.openFDA drugsfda record for tesamorelin (BLA022505, ORIG-1 2010-11-10, Type 1)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 7.FDA: List of approved NDAs for biological products that were deemed to be BLAs on March 23, 2020 (corrected)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 8.FDA: Notice to compounders, changes that affect compounding on March 23, 2020 (content current as of 03/05/2020)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 9.FDA guidance: Mixing, diluting, or repackaging biological products outside the scope of an approved BLA (Jan 2018), section II.CTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 10.FDA guidance: Compounded drug products that are essentially copies of a commercially available drug product under section 503A (footnote 2)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 11.FDA: Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 12.FDA: Bulk drug substances nominated for use in compounding under section 503B (updated Mar 21, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 13.FDA: Certain bulk drug substances that may present significant safety risks (Apr 22, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 14.HHS interim enforcement discretion for 503A peptide compounding, FR Doc. 2026-22192 (Oct 30, 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 15.FDA warning letter, NuScience Peptides LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 16.FDA warning letter, Royal Peptides LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 17.FDA warning letter, TXP Innovations LLC dba Tex Peptides (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 18.FDA warning letter, Peak Performance Peptides (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 19.FDA warning letter, Peptide Partners LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 20.Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-70. PMID 18057338Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 21.Falutz J et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr 2010;53(3):311-22. PMID 20101189Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 22.Makimura H et al. Metabolic effects of a GHRF in obese subjects with reduced GH secretion: an RCT. J Clin Endocrinol Metab 2012;97(12):4769-79. PMID 23015655Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 23.Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV 2019;6(12):e821-30. PMID 31611038Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 24.Baker LD et al. Effects of GHRH on cognitive function in adults with MCI and healthy older adults. Arch Neurol 2012;69(11):1420-9. PMID 22869065Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 25.ClinicalTrials.gov API v2, intervention "tesamorelin" (24 studies)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
- 26.PubMed eutils counts for tesamorelin (97 tiab; 21 RCT; 1 animal-only; 0 "compounded"; 4 oral/nasal/sublingual mentions; 7 with ipamorelin)Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026↩
- 27.openFDA FAERS, reports naming tesamorelin or EGRIFTA (data to 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 28.WADA Prohibited List 2026, S2.2 (GHRH and its analogues)Tier 1: regulator or registerwada-ama.orgread Nov 16, 2026↩
- 29.DEA controlled substances, alphabetical order (Nov 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 30.GENOTROPIN (somatropin) prescribing informationTier 1: regulator or registerdailymed.nlm.nih.govread Nov 16, 2026
- 31.Determination that GEREF (sermorelin acetate) was not withdrawn for reasons of safety or effectiveness, 78 FR (Mar 4, 2013)Tier 1: regulator or registergovinfo.govread Nov 16, 2026
- 32.Federal Register API document search: "tesamorelin" (5 results, newest 2023-01-26, an unrelated HISA rule) and "peptide compounding" since 2026-10-30 (only 2026-22192 relevant)Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
- 33.DailyMed SPL list for tesamorelin: EGRIFTA SV (SPL v9, published Jul 31, 2026) and EGRIFTA WR (SPL v2, published Aug 3, 2026)Tier 1: regulator or registerdailymed.nlm.nih.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.